PET/CT IN ASSESSING THE LYMPHOMA RESPONSE TO TREATMENT

2022

Closed access Metadata (CSL-JSON)
DOI 10.52532/2521-6414-2022-1-63-32-35
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice for diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. The study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. Methods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The patients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). Results: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved in 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. Conclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological techniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different stages of lymphoma treatment, providing new opportunities for personalized treatment